Teva launches generic Avodart capsules in the USA

12 October 2015

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) today announced the exclusive launch of the generic equivalent to Avodart (dutasteride) capsules, 0.5mg, in the USA. The branded drug is marketed by UK pharma major GlaxoSmithKline (LSE: GSK).

Dutasteride is a 5 alpha-reductase enzyme inhibitor and works by lowering production of a hormone called dihydrotestosterone (DHT). Dutasteride capsules are used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Teva says it was first to file for approval of its generic version of Avodart and expects to be exclusive for several weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK